Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Gilead Sciences, Inc.

NASDAQ

Market Cap.

81.83B

Avg. Volume

6.89M

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Gilead Sciences, Inc.!

Still processing it, give me a bit more time...

Gilead Sciences, Inc. News

Gilead Sciences, Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Website screenshot
HealthcareDrug Manufacturers - General
gilead.com

About Gilead Sciences, Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

Gilead Sciences, Inc. Earnings & Revenue

Gilead Sciences, Inc. Financials

Table Compare

Compare GILD metrics with:

   

Earnings & Growth

GILD

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

GILD

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

GILD

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

GILD

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Gilead Sciences, Inc. Income

Gilead Sciences, Inc. Balance Sheet

Gilead Sciences, Inc. Cash Flow

Gilead Sciences, Inc. Financials Over Time

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityStrong Sell
Return on AssetsSell
Debt/Equity RatioStrong Buy
Price/Earnings RatioSell
Price/Book RatioStrong Buy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Gilead Sciences, Inc. Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

3.0400

Payment DateDividendFrequency
2024-06-270.77Quarterly
2024-03-280.77Quarterly
2023-12-280.75Quarterly
2023-09-280.75Quarterly
2023-06-290.75Quarterly

Historical Market Cap

Shares Outstanding

Gilead Sciences, Inc. Executives

NameRole
Mr. Daniel P. O'DayChairman & Chief Executive Officer
Ms. Johanna MercierChief Commercial Officer
Dr. Merdad V. Parsey M.D., Ph.D.Chief Medical Officer
Mr. Andrew D. DickinsonChief Financial Officer
Ms. Deborah H. TelmanExecutive Vice President of Corporate Affairs, General Counsel & Corporate Secretary
NameRoleGenderDate of BirthPay
Mr. Daniel P. O'DayChairman & Chief Executive OfficerMale19646.99M
Ms. Johanna MercierChief Commercial OfficerFemale19703.1M
Dr. Merdad V. Parsey M.D., Ph.D.Chief Medical Officer19642.79M
Mr. Andrew D. DickinsonChief Financial OfficerMale19702.66M
Ms. Deborah H. TelmanExecutive Vice President of Corporate Affairs, General Counsel & Corporate SecretaryFemale19652.56M

Gilead Sciences, Inc. Insider Trades

Date8 May
NameBARTON JACQUELINE K
RoleDirector
TransactionAcquired
TypeA-Award
Shares2310
Date8 May
NameBARTON JACQUELINE K
RoleDirector
TransactionAcquired
TypeA-Award
Shares12648
Date8 May
NameLOVE TED W
RoleDirector
TransactionAcquired
TypeA-Award
Shares2310
Date8 May
NameLOVE TED W
RoleDirector
TransactionAcquired
TypeA-Award
Shares12648
Date8 May
NameRodriguez Javier
RoleDirector
TransactionAcquired
TypeA-Award
Shares2310
DateNameRoleTransactionTypeShares
8 MayBARTON JACQUELINE KDirectorAcquiredA-Award2310
8 MayBARTON JACQUELINE KDirectorAcquiredA-Award12648
8 MayLOVE TED WDirectorAcquiredA-Award2310
8 MayLOVE TED WDirectorAcquiredA-Award12648
8 MayRodriguez JavierDirectorAcquiredA-Award2310

Discover More

Streamlined Academy

Gilead Sciences, Inc.

NASDAQ

Market Cap.

81.83B

Avg. Volume

6.89M

Price

1W %

1M %

3M %

6M %

1Y %

YTD %

--

--

--

--

--

--

--

Gilead Sciences, Inc. News

Gilead Sciences, Inc. Score

Overall Score

Growth

Value

Quality

Moment.

Momentum

Stability

Gilead Sciences, Inc. Earnings & Revenue

Gilead Sciences, Inc. Income

Gilead Sciences, Inc. Balance Sheet

Gilead Sciences, Inc. Cash Flow

Gilead Sciences, Inc. Financials Over Time

Gilead Sciences, Inc. Executives

NameRole
Mr. Daniel P. O'DayChairman & Chief Executive Officer
Ms. Johanna MercierChief Commercial Officer
Dr. Merdad V. Parsey M.D., Ph.D.Chief Medical Officer
Mr. Andrew D. DickinsonChief Financial Officer
Ms. Deborah H. TelmanExecutive Vice President of Corporate Affairs, General Counsel & Corporate Secretary
NameRoleGenderDate of BirthPay
Mr. Daniel P. O'DayChairman & Chief Executive OfficerMale19646.99M
Ms. Johanna MercierChief Commercial OfficerFemale19703.1M
Dr. Merdad V. Parsey M.D., Ph.D.Chief Medical Officer19642.79M
Mr. Andrew D. DickinsonChief Financial OfficerMale19702.66M
Ms. Deborah H. TelmanExecutive Vice President of Corporate Affairs, General Counsel & Corporate SecretaryFemale19652.56M

Gilead Sciences, Inc. Insider Trades

Date8 May
NameBARTON JACQUELINE K
RoleDirector
TransactionAcquired
TypeA-Award
Shares2310
Date8 May
NameBARTON JACQUELINE K
RoleDirector
TransactionAcquired
TypeA-Award
Shares12648
Date8 May
NameLOVE TED W
RoleDirector
TransactionAcquired
TypeA-Award
Shares2310
Date8 May
NameLOVE TED W
RoleDirector
TransactionAcquired
TypeA-Award
Shares12648
Date8 May
NameRodriguez Javier
RoleDirector
TransactionAcquired
TypeA-Award
Shares2310
DateNameRoleTransactionTypeShares
8 MayBARTON JACQUELINE KDirectorAcquiredA-Award2310
8 MayBARTON JACQUELINE KDirectorAcquiredA-Award12648
8 MayLOVE TED WDirectorAcquiredA-Award2310
8 MayLOVE TED WDirectorAcquiredA-Award12648
8 MayRodriguez JavierDirectorAcquiredA-Award2310

Streamlined Academy

Website screenshot
HealthcareDrug Manufacturers - General
gilead.com

About Gilead Sciences, Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.

AI Analyst

AI

Streamlined AI Analyst

Hi I’m your personal financial assistant, click on one of the options below and I’ll help you analyze Gilead Sciences, Inc.!

Still processing it, give me a bit more time...

Gilead Sciences, Inc. Financials

Table Compare

Compare GILD metrics with:

   

Earnings & Growth

GILD

None

EPS (TTM) YoY Growth

--

--

Revenue (TTM) YoY Growth

--

--

 

Valuation (TTM)

GILD

None

Price/Earnings Ratio

--

--

Price/Sales Ratio

--

--

 

Profitability & Efficiency (TTM)

GILD

None

Net Profit Margin

--

--

Return on Equity

--

--

 

Financial Health (TTM)

GILD

None

Debt Ratio

--

--

Quick Ratio

--

--

 

Gilead Sciences, Inc. Dividends

Yield (TTM)Dividend (TTM) 

Infinity%

3.0400

Payment DateDividendFrequency
2024-06-270.77Quarterly
2024-03-280.77Quarterly
2023-12-280.75Quarterly
2023-09-280.75Quarterly
2023-06-290.75Quarterly

Gilead Sciences, Inc. Valuation

Project future cash flows and get the intrinsic value per share.

Start valuation modeling

Analysts Rating

Strong Buy

Buy

Hold

Sell

Strong Sell

Metrics Scores

MetricsScore
Discounted Cash FlowsStrong Buy
Return on EquityStrong Sell
Return on AssetsSell
Debt/Equity RatioStrong Buy
Price/Earnings RatioSell
Price/Book RatioStrong Buy

Price Targets


Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.

Historical Market Cap

Shares Outstanding

Discover More